CHI3L1 and glioblastoma: The strategy of blocking CHI3L1 with specific antibodies has been used in mouse models to decrease progression of melanoma [38–40], glioblastoma [41], lung [35, 42], pancreatic [35], colon [35] and breast cancer [16].